en · de · es
lab-handbook.peptides6823.com › Info › Thymosin Beta-4 Fragment Overview — Research Overview

Thymosin Beta-4 Fragment Overview — Research Overview

By Editorial Desk · published 2026-02-22 · last reviewed 2026-03-08 · Info

If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-03-08. Numbers and descriptions here follow the published literature rather than marketing material.

Thymosin Beta-4 Fragment Overview

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Handling, Storage, and Analytical Verification

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid as supplied
Water solubilitySolubleDissolves in aqueous media
Typical storage temperature-20 °CDry powder, desiccated, protected from light
Typical analytical methodRP-HPLC with mass spectrometryPurity from peak area; mass for identity
Common synonymsTβ4 fragment; thymosin beta-4 fragmentNaming varies by supplier and catalogue

Identity And Naming Background

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Related pages on this site

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Handling, Storage, and Quality Control

Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.

Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.

Identity and Physical Form

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

Background from the literature

=== Stratum corneum === The stratum corneum is typically 10–20 μm thick and consists of extracellular lipid-surrounded corneocytes. The lipophilic environment of the stratum corneum can serve as a reservoir for certain highly lipophilic molecules. Keratin found in the stratum corneum may provide great affinity with certain drugs. Both of these interactions can play a role in drug accumulation in the stratum corneum and the local drug action on skin disease.

liraglutide (Victoza for type 2 diabetes, Saxenda for weight management, manufactured by Novo Nordisk), approved in 2010/2014 dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014 semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for weight management, manufactured by Novo Nordisk), approved in 2021/2019/2021 tirzepatide (a GIP analog with dual GLP-1 receptor and GIP receptor agonism; Mounjaro for diabetes, Zepbound for weight management, manufactured by Eli Lilly), approved in 2022/2024 Discontinued:

=== Amplifying fluorescent polymer === Amplifying fluorescent polymer (AFP) is a promising new technology and is based on synthesized polymers which bind to explosive molecules and give an amplified signal upon detection. When compounds that are not polymers are utilized for such purpose, the quenching of the fluorescence by the traces of explosives is not detectable. When amplifying fluorescent polymer in thin films absorbs a photon of light, excited state polymers (excitons) are able to migrate along the polymer backbone and between the adjacent polymer films. These sensors were originally made in order to detect trinitrotoluene. In AFP, binding of one TNT molecule results in quenching of fluorescence significantly due to the conjugated structure of the polymers. It has been reported that in practice the polymers result in 100-1000 fold increase of amplification of the quenching response. "During its excited state lifetime, the exciton propagates by a random walk through a finite volume of the polymer film." Once TNT, or any other electron-deficient (i.e., electron accepting) molecule comes in contact with the polymer, a so-called low-energy ‘trap’ forms. "If the exciton migrates to the site of the bound electron-deficient molecule before transitioning back to the ground state, the exciton will be trapped (a non-radioactive process), and no fluorescence will be observed from the excitation event.

Eatza Pizza was a buffet-style restaurant chain founded in Arizona in 1997. In 2007, it was one of the largest all-buffet pizza chains in the United States, with 112 locations in 14 states and Puerto Rico.

Sources: en.wikipedia.org

Further detail

Collagen alpha-1(VII) chain is a protein that in humans is encoded by the COL7A1 gene. It is composed of a triple helical, collagenous domain flanked by two non-collagenous domains, and functions as an anchoring fibril between the dermal-epidermal junction in the basement membrane. Mutations in COL7A1 cause all types of dystrophic epidermolysis bullosa, and the exact mutations vary based on the specific type or subtype. It has been shown that interactions between the NC-1 domain of collagen VII and several other proteins, including laminin-5 and collagen IV, contribute greatly to the overall stability of the basement membrane.

== Development == The isopeptag was developed by dissecting the pilin protein (Spy0128) from Streptococcus pyogenes. Spy0128 contains two intramolecular isopeptide bonds, and to generate the isopeptag one of these bonds was split by removing the last β-strand in the protein.

== The Saint and the Sinners (1965–1968)| Airborne (1969–1970) == Ron next worked with The Saint and the Sinners (1965–1968) featuring lead singer Tommy Forrest (ex-The Monterays), keyboardist George Day, Si Sifer (drums), Dave Machan (vocals/guitar). The Saint and the Sinners started out as a typical mid 60's garage/dance band before evolving into a soul/horn band, not unlike Wilmer & the Dukes (another regionally popular band). The Saint and the Sinners fought it out with both The Dukes and The Monterays on the local dance circuit. The band could be seen regularly playing the hip clubs and dances of the era. These places include: Hewitt's, The Pin-O-Rama in Oswego, S.U. frat blasts, Carlsys, The Turn On in Downtown Syracuse, and other local high school dances. It was at this time that the Sinners made their first recordings "LIVE" (naturally) at St. Matthews School in East Syracuse. The Saint and the Sinners spent summer 1967 as the "virtual" house band of The Forest Hotel in Sylvan Beach, New York. ""The popularity of the band was established when we played all summer at The Forest Hotel," Ron states. "People of that generation still remember us from performing there. Stop in and ask Captain John at his restaurant in Sylvan Beach as to who was one of the best bands to play at the Forest." Soon after this engagement, the group underwent another split, with George Day leaving (he would later surface in The Monterays.) The Sinners soldiered on, acquiring saxophonist Frank Segroi and organist (and former Campus Walker) Larry Brennan. Ron-"We completely changed our style.

=== Vaccines === Gardasil (HPV vaccine) ($8.5 billion in 2024 revenues) is a vaccine against multiple serotypes of human papillomavirus (HPV), which is responsible for most cases of cervical cancer worldwide. ProQuad/M-M-R II/Varivax ($2.5 billion in 2024 revenues) is a combination MMRV vaccine against measles, mumps, rubella (German measles), and varicella (chickenpox). Vaxneuvance ($0.8 billion in 2024 revenues) is a pneumococcal conjugate vaccine. RotaTeq ($0.7 billion in 2024 revenues) is a rotavirus vaccine. Pneumovax 23 ($0.3 billion in 2024 revenues) is a pneumococcal polysaccharide vaccine.

==== Eukaryotic pathway ==== In eukaryotes such as yeasts, plants and animals, the synthesis processes are believed to happen in mitochondria. The first step is the acylation of glycerol-3-phosphate by a glycerol-3-phosphate acyltransferase. Then acylglycerol-3-phosphate can be once more acylated to form a phosphatidic acid (PA). With the help of the enzyme CDP-DAG synthase (CDS) (phosphatidate cytidylyltransferase), PA is converted into cytidinediphosphate-diacylglycerol (CDP-DAG). The following step is conversion of CDP-DAG to phosphatidylglycerol phosphate (PGP) by the enzyme PGP synthase, followed by dephosphorylation by PTPMT1 to form PG. Finally, a molecule of CDP-DAG is bound to PG to form one molecule of cardiolipin, catalyzed by the mitochondria-localized enzyme cardiolipin synthase (CLS).

Sources: en.wikipedia.org

Background from the literature

=== Social services === On November 15, 2018, the government announced it was eliminating three watchdog legislative offices, including the child and youth advocate. One of the biggest cuts, announced in the 2019 budget, was the $1 billion cut—over four years—to the Ministry of Community and Social Services. In February 2019, the government had announced changes to the Ontario Autism Program, which had over 20,000 children on a waiting list. Under Minister MacLeod and Fee, changes were made in "how children qualified, based on age and family income". During the revamping of the Program, support for children already receiving service, was clawed back which meant that families had to pay most of the bills for "very expensive behavioural therapies." This "outraged those in the autism community". The protests included a "huge rally at Queen's Park that could be heard inside the legislature and inundated Tory MPPs and Social Services Minister Lisa MacLeod with complaints." In response, the Ford government "scrambled to pour more money into the program and in early May [2019] announced consultations that would help shape further reforms to the system, moving toward one based on need." The Hamilton Spectator said that of all the "policy snafus", the funding of services for families of children with autism, was the one that bothered Ford the most.

== History == GeneDx was founded in 2000 by scientists Sherri Bale and John Compton from the National Institutes of Health (NIH). The company was established to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which limited commercial testing options existed at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, GeneDx was acquired by BioReference Laboratories and continued to operate as a subsidiary. In October 2016, Benjamin D. Solomon was appointed as managing director. In 2021, Katherine Stueland became CEO of GeneDx. GeneDx was acquired by Sema4 in 2022, and Stueland was named CEO of the combined company. In 2023, the combined company underwent a strategic transformation, refocusing on whole exome and genome sequencing in pediatrics, and changed its name to GeneDx. In 2025 GeneDx was named one of Fast Company's Most Innovative Companies, ranked No.2 in the Biotech category. The recognition highlighted the company's work in advancing genomic sequencing and data-driven approaches to improve rare disease diagnosis. GeneDx settled a patent dispute with Myriad Genetics in February 2015 after GeneDx launched a BRCA mutation breast cancer genetic screening test following the US Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. that concluded isolated gene sequences were patent ineligible.

Shorter polysaccharides, with 3 to 10 monomers, are called oligosaccharides. A fluorescent indicator-displacement molecular imprinting sensor was developed for discriminating saccharides. It successfully discriminated three brands of orange juice beverage. The change in fluorescence intensity of the sensing films resulting is directly related to the saccharide concentration.

=== Aggregation === Tropoelastin aggregates at physiological temperature due to interactions between hydrophobic domains in a process called coacervation. This process is reversible and thermodynamically controlled and does not require protein cleavage. The coacervate is made insoluble by irreversible crosslinking.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.

How does it differ from full thymosin beta-4?

The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.

Is human evidence available?

Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.

Can the powder be stored at room temperature?

Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.

Network